Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patient ≥ 18 years~2. Philadelphia chromosome positive newly diagnosed chronic myelogenous leukaemia (≤ 4 months) in first chronic phase.~3. Not previously treated with tyrosine kinase inhibitors other than imatinib~4. Prior treatment with imatinib during less than 13 weeks~5. Signed written inform consent~6. Women of childbearing potential (WOCBP) must be using an adequate method of contraception~Exclusion Criteria:~1. Patients with BCR-ABL positive, Philadelphia negative CML~2. Patient previously treated with TKI other than imatinib~3. Pregnancy~4. Active malignancy~5. Concurrent severe diseases which exclude the administration of therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: NO_INTERVENTION): cohort 3: Imatinib through dosage ≥ 1000 ng/ml
- Active comparator (Type: ACTIVE_COMPARATOR): Cohort 2 : Imatinib standard dose Imatinib through dosage \< 1000 ng/ml
- Experimental arm (Type: EXPERIMENTAL): Cohort 1 : dose adjustment based on trough plasmatic level value Imatinib through dosage \< 1000 ng/ml

Based on this trial design, predict the completion outcome and termination type (if applicable).